Research location
Manassas
Virginia, United States
Advertisement
Research activity in Manassas
Virginia, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 201 trials and 206 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Manassas
201 linked trials · page 1 of 5A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 DiabetesNCT07843485 · 2026-09-30 · 1 site observation
RECRUITING
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventNCT07783802 · 2026-08-27 · 1 site observation
RECRUITING
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusNCT07776509 · 2026-08-24 · 1 site observation
RECRUITING
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsNCT07797335 · 2026-08-24 · 1 site observation
RECRUITING
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightNCT07784270 · 2026-08-20 · 1 site observation
RECRUITING
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374 · 2026-07-17 · 1 site observation
RECRUITING
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant HypercholesterolemiaNCT07610278 · 2026-05-29 · 1 site observation
RECRUITING
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes MellitusNCT07527650 · 2026-05-18 · 1 site observation
RECRUITING
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 1 site observation
RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05 · 1 site observation
RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation
RECRUITING
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartNCT06935370 · 2025-05-20 · 1 site observation
RECRUITING
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation
RECRUITING
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation
RECRUITING
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureNCT06424288 · 2024-06-17 · 1 site observation
RECRUITING
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesNCT05390892 · 2022-09-26 · 1 site observation
RECRUITING
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 2026-10-26 · 1 site observation
NOT_YET_RECRUITING
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932 · 2026-05-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsNCT07502495 · 2026-03-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesNCT07284901 · 2026-01-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesNCT07284979 · 2025-12-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionNCT07128199 · 2025-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromeNCT07219602 · 2025-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)NCT07220629 · 2025-10-02 · 1 site observation
COMPLETED
A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872 · 2025-08-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT07081958 · 2025-07-29 · 1 site observation
COMPLETED
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNCT06966453 · 2025-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes MellitusNCT07055516 · 2025-05-08 · 1 site observation
COMPLETED
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityNCT06965413 · 2025-05-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · 2025-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · 2025-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · 2025-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 · 2025-04-22 · 1 site observation
COMPLETED
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)NCT06864104 · 2025-04-10 · 1 site observation
COMPLETED
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955 · 2025-03-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 · 2025-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseNCT06760637 · 2025-01-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesNCT06662539 · 2024-12-09 · 1 site observation
COMPLETED
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 · 2024-11-21 · 1 site observation
COMPLETED
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)NCT06660173 · 2024-11-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.NCT06579105 · 2024-10-08 · 1 site observation
COMPLETED
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related ComorbidityNCT06579092 · 2024-10-08 · 1 site observation
COMPLETED
A Phase IIb Study of AZD5462 in Patients With Chronic Heart FailureNCT06299826 · 2024-06-04 · 1 site observation
COMPLETED
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 · 2024-04-10 · 1 site observation
COMPLETED
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.NCT06268873 · 2024-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 · 2024-03-26 · 1 site observation
COMPLETED
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)NCT06272487 · 2024-02-29 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.